28/February/2022 Top Medical Bulletin

House dust mite sublingual immunotherapy effective for allergic asthma

Asthma affects quality of life to a greater extent, but house dust mite sublingual immunotherapy may be effective for allergic asthma, according to a recent study published in the Journal of Allergy and Clinical Immunology: In Practice.

House dust mite sublingual immunotherapy (HDM SLIT) effectively treats allergic rhinitis (AR). However, the evidence of HDM SLIT for allergic asthma remained limited. A study was conducted to systematically review the efficacy and safety of HDM SLIT tablets in patients with allergic asthma.

For more information check out the full story on the link below:

House dust mite sublingual immunotherapy effective for allergic asthma: Study

The CREDENCE trial: Canagliflozin does not impact risk of neuropathy events in diabetics

Diabetic neuropathy being the most common complication, High blood sugar (glucose) can injure nerves throughout your body..A post-hoc exploratory analysis of the CREDENCE trial has revealed that canagliflozin, a SGLT2 inhibitor, did not affect the risk of neuropathy. The findings of the study were published in the journal Diabetes & Metabolism. The trial included included patients with type 2 diabetes and kidney disease. They were randomized to receive canagliflozin 100mg daily or placebo. Neuropathy events were defined post-hoc as any reported adverse event consistent with a peripheral or autonomic neuropathy event. The results showed that the incidence of neuropathy events was similar in people randomized to canagliflozin and placebo. Canagliflozin had no impact on sensorimotor polyneuropathy, diabetic neuropathy, or non-autonomic neuropathy. The trial then further concluded, canagliflozin did not affect the risk of neuropathy events in the CREDENCE trial.